{"id":10409,"date":"2016-10-06T13:57:37","date_gmt":"2016-10-06T17:57:37","guid":{"rendered":"http:\/\/canadiantaskforce.ca\/?page_id=10409&#038;lang=fr"},"modified":"2024-04-16T10:12:11","modified_gmt":"2024-04-16T14:12:11","slug":"cancer-de-la-prostate-avantages-et-inconvenients","status":"publish","type":"page","link":"https:\/\/canadiantaskforce.ca\/fr\/tools-resources\/cancer-de-la-prostate-avantages-et-inconvenients\/","title":{"rendered":"Cancer de la prostate\u2014Outil de d\u00e9pistage aupr\u00e8s de 1000 personnes"},"content":{"rendered":"<div class='fullwidth-section  ' style=\"background-repeat:no-repeat;background-position:left top;\"><div class=\"container\"><div class=\"dt-sc-tabs-vertical2-container\"><ul id=\"menu-outilsressources\" class=\"dt-sc-tabs-vertical2-frame\"><li id=\"menu-item-14151\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-14151\"><a href=\"https:\/\/canadiantaskforce.ca\/fr\/tools-resources\/\">Outils de d\u00e9pistage<\/a><\/li>\n<li id=\"menu-item-14150\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-14150\"><a href=\"https:\/\/canadiantaskforce.ca\/fr\/?page_id=11228\">Vid\u00e9os<\/a><\/li>\n<\/ul><div class=\"dt-sc-tabs-vertical2-frame-content\"><div class='pdfdownload'><h5>Version PDF<\/h5><hr><div class='pdfdownload-text'> <a href=\"https:\/\/canadiantaskforce.ca\/wp-content\/uploads\/2016\/12\/CTFPHC_Prostate-Cancer_HarmsBenefits_French_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">PDF en couleur &#8211; Fran\u00e7ais<\/a><\/p>\n<p class=\"p1\"><span class=\"s1\"><a href=\"https:\/\/canadiantaskforce.ca\/wp-content\/uploads\/2024\/01\/CTFPHC_Prostate-Cancer_HarmsBenefits_FINAL_2023_Arabic.pdf\">PDF en couleur &#8211; Arabe<\/a><\/span><span class=\"s2\"><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\"><a href=\"https:\/\/canadiantaskforce.ca\/wp-content\/uploads\/2024\/01\/CTFPHC_Prostate-Cancer_HarmsBenefits_FINAL_2023_Punjabi.pdf\">PDF en couleur &#8211; Panjabi<\/a><\/span><span class=\"s2\"><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\"><a href=\"https:\/\/canadiantaskforce.ca\/wp-content\/uploads\/2024\/01\/CTFPHC_Prostate-Cancer_HarmsBenefits_FINAL_2023_Traditional-Chinese.pdf\">PDF en couleur &#8211; Chinois traditionnel\u00a0<\/a><\/span><\/p>\n<p><a href=\"https:\/\/canadiantaskforce.ca\/wp-content\/uploads\/2016\/12\/CTFPHC_Prostate-Cancer_HarmsBenefits_French_BW_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">PDF noir et blanc &#8211; Fran\u00e7ais<\/a><\/div><\/div>\n<div class='back'><h4><span class='fa fa-angle-left'><\/span>&nbsp;<a href='\/lignesdirectrives\/lignes-directrices-publiees\/cancer-de-la-prostate\/?lang=fr'>Retour<\/a><\/h4><\/div>\n<section id=\"the-canadian-task-force-on-preventive-health-care-recommends-against-screening-for-prostate-cancer-with-the-psa-test\" class=\"ctfphc-section\">\n<h3>LE GROUPE D\u2019\u00c9TUDE CANADIEN SUR LES SOINS DE SANT\u00c9 PR\u00c9VENTIFS D\u00c9CONSEILLE LE D\u00c9PISTAGE DU CANCER DE LA PROSTATE AU MOYEN DU DOSAGE DE L\u2019APS<\/h3>\n<ul>\n<li>Le G\u00c9CSSP est d\u2019avis que le l\u00e9ger avantage que peut pr\u00e9senter le d\u00e9pistage par dosage de l\u2019APS est surpass\u00e9 par les pr\u00e9judices potentiellement graves du d\u00e9pistage et du traitement qui s\u2019ensuivrait.<\/li>\n<li>Les hommes doivent comprendre que le dosage de l\u2019APS peut conduire \u00e0 des tests additionnels si le taux d\u2019APS se r\u00e9v\u00e8le \u00e9lev\u00e9.<\/li>\n<li>Pour sauver une vie, il faudrait diagnostiquer le cancer de la prostate chez 27 hommes de plus.<\/li>\n<\/ul>\n<\/section>\n<section id=\"results-of-screening-1000-men-with-the-psa-test\" class=\"ctfphc-section\">\n<h3>R\u00c9SULTATS DU D\u00c9PISTAGE AUPR\u00c8S DE 1000 HOMMES AU MOYEN DU DOSAGE DE L\u2019APS<\/h3>\n<\/section>\n<section id=\"what-are-my-risks-if-i-dont-get-screened\" class=\"ctfphc-section\">\n<h3>QUELS SONT MES RISQUES SI JE NE SUBIS PAS LE D\u00c9PISTAGE?<\/h3>\n<ul>\n<li>Chez les hommes <em>soumis au d\u00e9pistage<\/em> par dosage de l\u2019APS, le risque de mourir d\u2019un cancer de la prostate est de 5 sur 1000<\/li>\n<li>Chez les hommes <em>non soumis au d\u00e9pistage<\/em> par dosage de l\u2019APS, le risque de mourir d\u2019un cancer de la prostate est de 6 sur 1000<\/li>\n<\/ul>\n<section id=\"complications-of-treatment-for-prostate-cancer\" class=\"ctfphc-section\">\n<h3>COMPLICATIONS DU TRAITEMENT DU CANCER DE LA PROSTATE<\/h3>\n<p>Pour chaque tranche de 1000 hommes qui re\u00e7oivent un traitement pour le cancer de la prostate :<\/p>\n<ul>\n<li>de 114 \u00e0 214 auront des complications \u00e0 court terme telles qu\u2019infections, chirurgies additionnelles et transfusions sanguines<\/li>\n<li>de 127 \u00e0 442 souffriront de dysfonction \u00e9rectile \u00e0 long terme<\/li>\n<li>jusqu\u2019\u00e0 178 souffriront d\u2019incontinence urinaire<\/li>\n<li>4 ou 5 mourront de complications du traitement du cancer de la prostate<\/li>\n<\/ul>\n<\/section>\n<section id=\"note\" class=\"ctfphc-section\">\n<h3>Note<\/h3>\n<p>Les statistiques qui ont servi au calcul des bienfaits et pr\u00e9judices proviennent de l\u2019European Randomized Study of Screening for Prostate Cancer (ERSPC).<\/p>\n<\/section>\n<\/section>\n<\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":8979,"parent":10330,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[220,218],"tags":[],"class_list":["post-10409","page","type-page","status-publish","has-post-thumbnail","hentry","category-cancer-de-la-prostate","category-outils"],"acf":[],"_links":{"self":[{"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/pages\/10409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/comments?post=10409"}],"version-history":[{"count":15,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/pages\/10409\/revisions"}],"predecessor-version":[{"id":28704,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/pages\/10409\/revisions\/28704"}],"up":[{"embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/pages\/10330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/media\/8979"}],"wp:attachment":[{"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/media?parent=10409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/categories?post=10409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadiantaskforce.ca\/fr\/wp-json\/wp\/v2\/tags?post=10409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}